| M05BA04 |
M05BA04 Alendronic acid |
| M05BA05 |
M05BA05 Tiludronic acid |
| M05BA06 |
M05BA06 Ibandronic acid |
| M05BA07 |
M05BA07 Risedronic acid |
| M05BA08 |
M05BA08 Zoledronic acid |
| M05BB |
M05BB Bisphosphonates, combinations |
| M05BB01 |
M05BB01 etidronic acid and calcium, sequential |
| M05BB02 |
M05BB02 risedronic acid and calcium, sequential |
| M05BB03 |
M05BB03 alendronic acid and colecalciferol |
| M05BB04 |
M05BB04 risedronic acid, calcium and colecalciferol, sequential |
| M05BB05 |
M05BB05 alendronic acid, calcium and colecalciferol, sequential |
| M05BB06 |
M05BB06 alendronic acid and alfacalcidol, sequential |
| M05BB07 |
M05BB07 risedronic acid and colecalciferol |
| M05BB08 |
M05BB08 zoledronic acid, calcium and colecalciferol, sequential |
| M05BB09 |
M05BB09 ibandronic acid and colecalciferol |
| M05BC |
M05BC Bone morphogenetic proteins |
| M05BC01 |
M05BC01 dibotermin alfa |
| M05BC02 |
M05BC02 eptotermin alfa |
| M05BX |
M05BX Other drugs affecting bone structure and mineralization |
| M05BX01 |
M05BX01 ipriflavone |
| M05BX02 |
M05BX02 aluminium chlorohydrate |
| M05BX03 |
M05BX03 strontium ranelate |
| M05BX04 |
M05BX04 denosumab |
| M05BX05 |
M05BX05 burosumab |
| M05BX06 |
M05BX06 Romosozumab |
| M05BX53 |
M05BX53 strontium ranelate and colecalciferol |
| M09 |
M09 Other drugs for disorders of the musculo-skeletal system |
| M09A |
M09A Other drugs for disorders of the musculo-skeletal system |
| M09AA |
M09AA Quinine and derivatives |
| M09AA01 |
M09AA01 hydroquinine |